Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Dyne Therapeutics, Inc.

Monday.com ( ($MNDY) ) has shared an announcement. At its annual general meeting held on August 6, 2026 in Tel Aviv, monday.com shareholders re-ele...

monday.com shareholders back board, pay policies and auditor at August AGM

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Grid Dynamics Holdings (GDYN), Daqo New Energy (DQ...

Analysts’ Opinions Are Mixed on These Technology Stocks: Grid Dynamics Holdings (GDYN), Daqo New Energy (DQ) and Qualcomm (QCOM)

In a report released yesterday, Martin Auster from Raymond James maintained a Buy rating on Dyne Therapeutics, with a price target of $40.00. The c...

Raymond James Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO...

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO)

Grid Dynamics Holdings, Inc. (GDYN) has disclosed a new risk, in the Debt & Financing category. Grid Dynamics Holdings, Inc. faces capital allocati...

Grid Dynamics’ Discretionary $50 Million Buyback Program Raises Capital Allocation and Confidence Concerns

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Illumina (ILMN), Dyne Therapeutics (DYN) and Brist...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Illumina (ILMN), Dyne Therapeutics (DYN) and Bristol-Myers Squibb (BMY)

In a report released yesterday, Luca Issi from RBC Capital reiterated a Buy rating on Dyne Therapeutics, with a price target of $35.00. The company...

RBC Capital Remains a Buy on Dyne Therapeutics (DYN)

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Dyne Therapeutics, with a price target of $47.00. Accordi...

Piper Sandler Sticks to Its Buy Rating for Dyne Therapeutics (DYN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mach7 Technologies (TDMMF) and Dyne Therapeutics (DY...

Analysts Offer Insights on Healthcare Companies: Mach7 Technologies (OtherTDMMF) and Dyne Therapeutics (DYN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Centene (CNC) and Dyne Therapeutics (DYN). Centene...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Centene (CNC) and Dyne Therapeutics (DYN)

An announcement from Dyne Therapeutics ( ($DYN) ) is now available. On July 21, 2026, Dyne Therapeutics priced an upsized underwritten public offer...

Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACA...

Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD)

Dyne Therapeutics ( ($DYN) ) just unveiled an announcement. On July 20, 2026, Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Adminis...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DYN	$26.50	+0.95%	557.22K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DYN	$26.50	+1.0%	557.22K
3
4
5
6

DYN

DYN

Get Dyne Therapeutics, Inc. Data in Excel

Get Dyne Therapeutics, Inc. Data in Excel